Related Experiment Video
Updated: Mar 26, 2026
Fabrication of a Bioactive, PCL-based "Self-fitting" Shape Memory Polymer Scaffold
Published on: October 23, 2015
Next-generation resorbable polymer scaffolds with surface-precipitated calcium phosphate coatings
Jinku Kim1, Maria Hanshella R Magno1, Ophir Ortiz1
1Bone Tissue Engineering Center, Department of Biomedical Engineering, Carnegie Mellon University, Pittsburgh, PA 15219, USA, Department of Bio and Chemical Engineering, Hongik University, Sejong, Korea 339-701 and Department of Chemistry and Chemical Biology and New Jersey Center for Biomaterials, Rutgers, The State University of New Jersey, Piscataway, NJ 08854, USA.
Tyrosine-derived polycarbonate scaffolds (E1001(1k)) coated with dicalcium phosphate dihydrate (CP) show significant bone regeneration. This enhanced scaffold (E1001(1k) + CP) demonstrated superior osteoconductivity compared to bone matrix minerals (BMM) enhanced scaffolds and a commercial bone graft substitute.
Area of Science:
- Biomaterials Science
- Orthopedic Research
- Regenerative Medicine
Background:
- Next-generation bone graft therapies integrate resorbable polymers with bioactive components.
- Tyrosine-derived polycarbonates offer degradable, non-toxic, and osteoconductive properties for orthopedic applications.
Purpose of the Study:
- To evaluate E1001(1k) scaffolds enhanced with dicalcium phosphate dihydrate (CP) or bone matrix minerals (BMM) for bone regeneration.
- To compare their efficacy against a commercially available bone graft substitute (ChronOS).
Main Methods:
- Fabrication of porous E1001(1k) scaffolds with CP or BMM coatings.
- Utilized a rabbit calvaria critical-sized defect model.
- Assessed bone formation via micro-computerized tomography (μCT) and histology at 2, 4, 6, 8, and 12 weeks.
Main Results:
- E1001(1k) + CP scaffolds supported significant bone formation, outperforming E1001(1k) + BMM scaffolds.
- A trend favored E1001(1k) + CP over the commercial bone graft substitute, reaching statistical significance at 6 weeks.
- E1001(1k) + CP showed progressive bone formation throughout the scaffold over time, unlike other groups.
Conclusions:
- E1001(1k) + CP demonstrates promising osteoregenerative potential.
- Further investigation of E1001(1k) + CP for bone regeneration applications is warranted.
